Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for <i>Helicobacter pylori</i> eradication in dyspepsia
<b>Background/Aim: </b><i>Helicobacter pylori</i> (<i>H pylori</i>)<b> </b> plays an important role in the pathogenesis of chronic gastritis, peptic ulcer disease, and gastric neoplasms<b> . </b> Therefore, it is necessary to<b> <...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2009-01-01
|
Series: | The Saudi Journal of Gastroenterology |
Subjects: | |
Online Access: | http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2009;volume=15;issue=4;spage=225;epage=228;aulast=Agah |
Summary: | <b>Background/Aim: </b><i>Helicobacter pylori</i> (<i>H pylori</i>)<b> </b> plays an important role in the pathogenesis of chronic gastritis, peptic ulcer disease, and gastric neoplasms<b> . </b> Therefore, it is necessary to<b> </b> select an effective regimen for <i>H pylori</i> eradication<b> . </b> The aim of this study was to<b> </b> compare the efficacy of two quadruple-therapy regimens-one with<b> </b> azithromycin and the other with metronidazole-for <i>H pylori</i> eradication in patients with dyspepsia.<b> Materials and Methods: </b> In this double-blind randomized clinical trial conducted in Rasoule-Akram Hospital in 2006, we included 60 patients (aged 15-70 years) who had dyspepsia and <i>H pylori</i> infection as diagnosed by upper gastrointestinal endoscopy and rapid urease test. Patients were randomly assigned to receive a quadruple-therapy regimen for 2 weeks: 1) the MAO-B group (<i>n </i>= 30) received metronidazole 500 mg b.i.d, amoxicillin 1g b.i.d, omeprazole 20 mg b.i.d, and bismuth 240 mg b.i.d and 2) the AAO-B group (<i>n</i> = 30) received azithromycin 500 mg once daily for 1 week and amoxicillin 1g b.i.d, omeprazole 20 mg b.i.d, and bismuth 240 mg b.i.d for 2 weeks). <i>H pylori</i> eradication was assessed by the rapid urease test (RUT) 2 months after the cessation of treatment<b> . Results: </b><i>H pylori</i> was eradicated in 68% and 69% of patients in the MAO-B and AAO-B groups, respectively. There was no significant difference in <i>H pylori</i> eradication rates between the two groups (<i>P</i> = 0.939).<b> Conclusion: </b> No significant difference exists between the two quadruple-therapy regimens that were tested. |
---|---|
ISSN: | 1319-3767 1998-4049 |